Pancreatic Cancer Data

Market Dynamics and Outcomes

Pancreatic cancer is a hard-to-treat tumor type with the lowest survival rate of cancers covered by the American Cancer Society.  Onivyde and Tarceva are the two most established treatments for metastatic pancreatic cancer (in combination with chemo) but show only single-digit response rates and PFS of ~3 months.  Thus, there is high unmet need for new therapeutics that can “debulk” the tumor and make it more likely for the patient to be a candidate for resection surgery which increases survival significantly. There are over 60,000 new cases of pancreatic cancer in the US every year.